Next Article in Journal
Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response
Previous Article in Journal
Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma

Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?

Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11835 Cairo, Egypt
Experimental and Clinical Research Center, Charité—Universitätsmedizin Berlin, 10117 Berlin, Germany
Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany
German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
Author to whom correspondence should be addressed.
These authors have contributed equally to the manuscript.
Academic Editor: Chae-OK Yun
Cells 2021, 10(2), 302;
Received: 20 December 2020 / Revised: 21 January 2021 / Accepted: 28 January 2021 / Published: 2 February 2021
(This article belongs to the Section Cell Signaling)
Since the beginning of the SARS-CoV-2(severe acute respiratory syndrome-coronavirus-2) pandemic, a race to develop a vaccine has been initiated, considering the massive and rather significant economic and healthcare hits that this virus has caused. The pathophysiology occurring following COVID-19(coronavirus disease-2019) infection has given hints regarding the supportive and symptomatic treatments to establish for patients, as no specific anti-SARS-CoV-2 is available yet. Patient symptoms vary greatly and range from mild symptoms to severe fatal complications. Supportive treatments include antipyretics, antiviral therapies, different combinations of broad-spectrum antibiotics, hydroxychloroquine and plasma transfusion. Unfortunately, cancer patients are at higher risk of viral infection and more likely to develop serious complications due to their immunocompromised state, the fact that they are already administering multiple medications, as well as combined comorbidity compared to the general population. It may seem impossible to find a drug that possesses both potent antiviral and anticancer effects specifically against COVID-19 infection and its complications and the existing malignancy, respectively. Thymoquinone (TQ) is the most pharmacologically active ingredient in Nigella sativa seeds (black seeds); it is reported to have anticancer, anti-inflammatory and antioxidant effects in various settings. In this review, we will discuss the multiple effects of TQ specifically against COVID-19, its beneficial effects against COVID-19 pathophysiology and multiple-organ complications, its use as an adjuvant for supportive COVID-19 therapy and cancer therapy, and finally, its anticancer effects. View Full-Text
Keywords: SARS-CoV-2; COVID-19; cancer; thymoquinone; apoptosis; COVID-19 treatments; anticancer drugs; COVID-19 complications; Nrf2; GRP78; RAS SARS-CoV-2; COVID-19; cancer; thymoquinone; apoptosis; COVID-19 treatments; anticancer drugs; COVID-19 complications; Nrf2; GRP78; RAS
Show Figures

Figure 1

MDPI and ACS Style

Elgohary, S.; Elkhodiry, A.A.; Amin, N.S.; Stein, U.; El Tayebi, H.M. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? Cells 2021, 10, 302.

AMA Style

Elgohary S, Elkhodiry AA, Amin NS, Stein U, El Tayebi HM. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? Cells. 2021; 10(2):302.

Chicago/Turabian Style

Elgohary, Sawsan, Aya A. Elkhodiry, Nada S. Amin, Ulrike Stein, and Hend M. El Tayebi. 2021. "Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?" Cells 10, no. 2: 302.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop